GENETIC MARKERS FOR PROGNOSIS OF RHEUMATOID ARTHRITIS TREATMENT EFFICACY
摘要
<p>The present invention discloses markers useful in predicting the responsiveness of a subject having, or at risk of developing rheumatoid arthritis (RA) to treatment with anti- TNFa agents. Particularly, the present invention discloses the allelic configuration of the CD6 gene and/or the STXBP6 gene which is indicative of the degree of responsiveness to anti-TNFa treatment of RA.</p>
